Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Plos One|March 7, 2017
Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44Deborah Wessels, Daniel F Lusche, Edward Voss, et al.
Annals of Surgical Oncology|June 26, 2016
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical TrialRobert H I Andtbacka, Merrick Ross, Igor Puzanov, et al.
Oncoimmunology|October 15, 2021
An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic MelanomaMerve Hasanov, Denái R Milton, William H Sharfman, et al.
Antioxidants (Basel, Switzerland)|May 25, 2024
Superoxide Dismutase Mimetic Avasopasem Manganese Enhances Radiation Therapy Effectiveness in Soft Tissue Sarcomas and Accelerates Wound HealingAmira Zaher, Kranti A Mapuskar, Michael S Petronek, et al.
Cell Reports. Medicine|March 7, 2025
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignanciesJuanita S Lopez, Mohammed Milhem, Marcus O Butler, et al.
Cell Reports|March 19, 2020
Cancer Cells Resist Mechanical Destruction in Circulation via RhoA/Actomyosin-Dependent Mechano-AdaptationDevon L Moose, Benjamin L Krog, Tae-Hyung Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2BDiwakar Davar, Zeynep Eroglu, Mohammed Milhem, et al.
British Journal of Cancer|May 29, 2021
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomasBrian Schulte, Nisha Mohindra, Mohammed Milhem, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2021
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcomaMark Agulnik, Brian Schulte, Steven Robinson, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
Pageof 8